|Bid||5.10 x 800|
|Ask||5.55 x 1100|
|Day's Range||5.30 - 5.69|
|52 Week Range||4.95 - 18.24|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
BOSTON, December 01, 2021--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company’s organizational efficiency and advancing its pipeline of products.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
BOSTON, November 10, 2021--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two upcoming virtual investor conferences: